PF 9104

Drug Profile

PF 9104

Latest Information Update: 16 Sep 1996

Price : $50

At a glance

  • Originator Almirall-Prodesfarma
  • Class Antihypertensives; Ischaemic heart disorder therapies; Peripheral vasodilators; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris

Most Recent Events

  • 16 Sep 1996 Discontinued-Preclinical for Angina pectoris in Spain (Unknown route)
  • 29 May 1995 New profile
  • 29 May 1995 Preclinical development for Angina pectoris in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top